Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.86 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5612428 | 1.00 | CCR5 (0.86) | CCR5CYP2C9CYP2D6CXCR4 | |
| SCHEMBL6188499 | 1.00 | CCR5 (0.86) | CCR5CYP2C9CYP2D6CXCR4 | |
| SCHEMBL4828446 | 0.96 | CCR5 (0.80) | CCR5CYP2C9CYP2D6CXCR4 | |
| Hydrochloric Acid SCHEMBL6191043 | 0.96 | CCR5 (0.84) | CCR5CYP2C9CYP2D6CXCR4 | |
| Hydrochloric Acid SCHEMBL6186201 | 0.96 | CCR5 (0.84) | CCR5CYP2C9CYP2D6CXCR4 | |
| Hydrochloric Acid SCHEMBL6189370 | 0.94 | CCR5 (0.78) | CCR5CYP2C9CYP2D6CXCR4 | |
| Hydrochloric Acid SCHEMBL6188772 | 0.94 | CCR5 (0.78) | CCR5CYP2C9CYP2D6CXCR4 | |
| SCHEMBL5349578 | 0.93 | CCR5 (0.81) | CCR5CYP2C9CYP2D6CXCR4 | |
| Hydrochloric Acid SCHEMBL6190158 | 0.93 | CCR5 (0.76) | CCR5CYP2C9CYP2D6CXCR4 | |
| SCHEMBL6012835 | 0.93 | CCR5 (1.00) | CCR5CYP2C9CYP2D6CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | claimed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | claimed |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | PANASONIC CORPORATION (JP) | 2004-05-20 | — | — | US | claimed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | claimed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | disclosed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | NONO, NAA15, USO1 | CCR5 369/4885CYP2C9 860/4885CYP2D6 1514/4885 |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | CXCR5, CCL11, ACKR3 | CCR5 5/4885CYP2C9 692/4885CYP2D6 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.